{Reference Type}: Journal Article
{Title}: Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics.
{Author}: Jiang Y;Wu L;Zhu X;Bian H;Gao X;Xia M;
{Journal}: Lipids Health Dis
{Volume}: 23
{Issue}: 1
{Year}: 2024 Apr 2
{Factor}: 4.315
{DOI}: 10.1186/s12944-024-02092-2
{Abstract}: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease that affects over 30% of the world's population. For decades, the heterogeneity of non-alcoholic fatty liver disease (NAFLD) has impeded our understanding of the disease mechanism and the development of effective medications. However, a recent change in the nomenclature from NAFLD to MASLD emphasizes the critical role of systemic metabolic dysfunction in the pathophysiology of this disease and therefore promotes the progress in the pharmaceutical treatment of MASLD. In this review, we focus on the mechanism underlying the abnormality of hepatic lipid metabolism in patients with MASLD, and summarize the latest progress in the therapeutic medications of MASLD that target metabolic disorders.